Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR1313167

— · C

0ce74a5c-4870-57f4-8b91-84448298d321

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
C
subtype
C

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • HYPOXIA+0.530
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.490
  • TNFA_SIGNALING_VIA_NFKB+0.490
  • HEDGEHOG_SIGNALING+0.360
  • GLYCOLYSIS+0.350
  • MTORC1_SIGNALING+0.320
  • PANCREAS_BETA_CELLS+0.320
  • P53_PATHWAY+0.310
  • TGF_BETA_SIGNALING+0.310
  • E2F_TARGETS+0.300

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.620
  • INTERFERON_GAMMA_RESPONSE-0.370
  • ALLOGRAFT_REJECTION-0.270
  • APICAL_SURFACE-0.110
  • MITOTIC_SPINDLE-0.090
  • DNA_REPAIR-0.070
  • WNT_BETA_CATENIN_SIGNALING-0.070
  • FATTY_ACID_METABOLISM-0.040
  • MYC_TARGETS_V2-0.040
  • BILE_ACID_METABOLISM-0.020

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MBCProject_0006_T3_RNA
breast-umap@18
—A0.836
2BSR_06_0059_A2_S99
breast-umap@18
—F0.822
3SRR33532814
breast-umap@18
—C0.818
4SRR8943009
bladder-landscape@3
——0.816
5ERR2278862
head-neck@1
——0.808
6SRR8518155
breast-umap@18
—E0.805
7TCGA-77-7338-01A-11R-2045-07
lung-landscapes@6
—cohortSQ20.766
8MNG1297
mng-umap@100
——0.763
9TCGA-18-3417-01A-01R-1443-07
lung-landscapes@6
—cohortSQ10.754
10BS_MWWZBQ60
brain-umap@2
high-grade glioma—0.753

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 39 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
HYPOXIA0.530Idelalisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.490Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.490Inavolisib— uncovered
HEDGEHOG_SIGNALING0.360Inavolisib— uncovered
GLYCOLYSIS0.350Inavolisib— uncovered
MTORC1_SIGNALING0.320Inavolisib— uncovered
PANCREAS_BETA_CELLS0.320Cobimetinib— uncovered
P53_PATHWAY0.310Idelalisib— uncovered
TGF_BETA_SIGNALING0.310Inavolisib— uncovered
E2F_TARGETS0.300Inavolisib— uncovered
ANGIOGENESIS0.260Remibrutinib— uncovered
CHOLESTEROL_HOMEOSTASIS0.260Remibrutinib— uncovered
MYC_TARGETS_V10.260Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.250Remibrutinib— uncovered
ESTROGEN_RESPONSE_LATE0.240Idelalisib— uncovered
KRAS_SIGNALING_DN0.240Remibrutinib— uncovered
UV_RESPONSE_DN0.220Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.210Inavolisib— uncovered
UV_RESPONSE_UP0.210Idelalisib— uncovered
G2M_CHECKPOINT0.200Inavolisib— uncovered